Paper · 38765604

Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: An in vitro and in vivo study.

Fang Y and 8 others. J Orthop Translat, 2024. Cited by 34 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: An in vitro and in vivo study. Papers, record 38765604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38765604

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: An in vitro and in vivo study.; PubMed
Journal: J Orthop Translat; PubMed
Year: 2024; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/38765604/; PubMed
DOI: https://doi.org/10.1016/j.jot.2024.04.004; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11099199/; PubMed
The journal: https://conductscience.org/library/journal-index/101625127; PubMed
Citations, by iCite: 34; iCite
Relative citation ratio, by iCite: 6.82, provisional; iCite
Revised in PubMed: 2024-05-21; PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Fang Y	Yuqin
2	Lou C	Chao
3	Lv J	Junlei
4	Zhang C	Chaoyang
5	Zhu Z	Ziteng
6	Hu W	Wei
7	Chen H	Hua
8	Sun L	Liaojun
9	Zheng W	Wenhao

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	26,132,855	Imperialine and Verticinone from Bulbs of Fritillaria wabuensis Inhibit Pro-inflammatory Mediators in LPS-stimulated RAW 264.7 Macrophages.	Planta Med	2015	https://conductscience.org/library/papers/26132855	PubMed
2	29,393,464	NLRP1 and NLRP3 inflammasomes mediate LPS/ATP‑induced pyroptosis in knee osteoarthritis.	Mol Med Rep	2018	https://conductscience.org/library/papers/29393464	PubMed
3	19,422,910	A powerful and flexible linear mixed model framework for the analysis of relative quantification RT-PCR data.	Genomics	2009	https://conductscience.org/library/papers/19422910	PubMed
4	36,898,572	Sipeimine attenuates PM2.5-induced lung toxicity via suppression of NLRP3 inflammasome-mediated pyroptosis through activation of the PI3K/AKT pathway.	Chem Biol Interact	2023	https://conductscience.org/library/papers/36898572	PubMed
5	36,199,358	XMU-MP-1 attenuates osteoarthritis via inhibiting cartilage degradation and chondrocyte apoptosis.	Front Bioeng Biotechnol	2022	https://conductscience.org/library/papers/36199358	PubMed
6	21,958,967	Antitussive, expectorant and anti-inflammatory alkaloids from Bulbus Fritillariae Cirrhosae.	Fitoterapia	2011	https://conductscience.org/library/papers/21958967	PubMed
7	29,436,380	Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.	Br J Sports Med	2018	https://conductscience.org/library/papers/29436380	PubMed
8	33,096,361	Inhibition of PI3K/Akt/NF-κB signaling by Aloin for ameliorating the progression of osteoarthritis: In vitro and in vivo studies.	Int Immunopharmacol	2020	https://conductscience.org/library/papers/33096361	PubMed
9	32,073,014	Glycyrrhizin inhibits osteoarthritis development through suppressing the PI3K/AKT/NF-κB signaling pathway in vivo and in vitro.	Food Funct	2020	https://conductscience.org/library/papers/32073014	PubMed
10	29,540,226	Vasoactive intestinal peptide alleviates osteoarthritis effectively via inhibiting NF-κB signaling pathway.	J Biomed Sci	2018	https://conductscience.org/library/papers/29540226	PubMed

1 to 10 of 55

See all 55 references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMID	Title	Journal	Year	In Papers	Source
42,978,697	Hupehenine suppresses tumor cell phenotypes and modulates macrophage marker profiles in a diabeticmimetic colorectal cancer model.	Front Pharmacol	2026	https://conductscience.org/library/papers/42978697	PubMed
42,643,917	Insights Into the HIF-1α-Mediated NLRP3 Pyroptosis Pathway in the Regulation of Musculoskeletal Diseases in the High-Altitude Environment.	J Inflamm Res	2026	https://conductscience.org/library/papers/42643917	PubMed
42,528,752	Sophoridine attenuates osteoarthritis progression: association with suppression of chondrocyte pyroptosis via inhibiting NF-κB signaling pathway.	Front Pharmacol	2026	https://conductscience.org/library/papers/42528752	PubMed
42,357,289	Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological Perspectives.	Pharmaceutics	2026	https://conductscience.org/library/papers/42357289	PubMed
42,220,035	Astragalus Polysaccharides Attenuate LPS-Induced Degenerative Responses in Primary Rat Chondrocytes linked to the NLRP3/CASPASE-1 Axis.	J Musculoskelet Neuronal Interact	2026	https://conductscience.org/library/papers/42220035	PubMed
42,217,061	Musculoskeletal degeneration and cardiovascular aging: a narrative review of shared mechanobiological pathways.	Mol Biol Rep	2026	https://conductscience.org/library/papers/42217061	PubMed
42,120,779	Ginsenoside Rh2 attenuates pyroptosis by inhibiting the PAFR/NF-κB signaling pathway in an osteoarthritis cell model.	Protoplasma	2026	https://conductscience.org/library/papers/42120779	PubMed
42,062,631	ELF3/miR-9-5p/NFKB1 axis promotes the progression of osteoarthritis by triggering NLRP3-mediated cell pyroptosis.	Immunol Res	2026	https://conductscience.org/library/papers/42062631	PubMed
41,851,615	Dendrophenol modulates the LRRK1/PIK3AP1 signaling axis: a novel strategy to mitigate inflammation and pyroptosis in gouty arthritis.	BMC Immunol	2026	https://conductscience.org/library/papers/41851615	PubMed
41,742,252	Glibenclamide attenuates osteoarthritis by suppressing NLRP3 inflammasome activation in synovial macrophages through the MAPK pathway.	J Transl Med	2026	https://conductscience.org/library/papers/41742252	PubMed

1 to 10 of 24

See all 24 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38765604

GET https://conductscience.org/api/papers/v1/38765604/references?page=2

API reference For AI assistants